307 related articles for article (PubMed ID: 21937700)
41. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.
Lasa A; Carricondo MT; Carnicer MJ; Perea G; Aventín A; Nomdedeu JF
Haematologica; 2006 Sep; 91(9):1283-4. PubMed ID: 16956837
[TBL] [Abstract][Full Text] [Related]
42. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
43. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
44. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
[TBL] [Abstract][Full Text] [Related]
45. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
Sasaki K; Tsujimoto S; Miyake M; Uchiyama Y; Ikeda J; Yoshitomi M; Shimosato Y; Tokumasu M; Matsuo H; Yoshida K; Ohki K; Kaburagi T; Yamato G; Hara Y; Takeuchi M; Kinoshita A; Tomizawa D; Taga T; Adachi S; Tawa A; Horibe K; Hayashi Y; Matsumoto N; Ito S; Shiba N
Br J Haematol; 2021 Jul; 194(2):414-422. PubMed ID: 34120331
[TBL] [Abstract][Full Text] [Related]
46. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
[TBL] [Abstract][Full Text] [Related]
48. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
[TBL] [Abstract][Full Text] [Related]
49. Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia.
Ko RM; Kim HG; Wolff L; Klug CA
Leuk Res; 2008 Jul; 32(7):1101-11. PubMed ID: 18037485
[TBL] [Abstract][Full Text] [Related]
50. Dominant negative effects of the AML1/ETO fusion oncoprotein.
Fenske TS; Pengue G; Graubert TA
Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635
[TBL] [Abstract][Full Text] [Related]
51. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
[TBL] [Abstract][Full Text] [Related]
52. Contribution of an aged microenvironment to aging-associated myeloproliferative disease.
Vas V; Wandhoff C; Dörr K; Niebel A; Geiger H
PLoS One; 2012; 7(2):e31523. PubMed ID: 22363661
[TBL] [Abstract][Full Text] [Related]
53. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
Tian Y; Wang G; Hu Q; Xiao X; Chen S
J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
[TBL] [Abstract][Full Text] [Related]
54. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
[TBL] [Abstract][Full Text] [Related]
55. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice.
Yamashita N; Osato M; Huang L; Yanagida M; Kogan SC; Iwasaki M; Nakamura T; Shigesada K; Asou N; Ito Y
Br J Haematol; 2005 Nov; 131(4):495-507. PubMed ID: 16281942
[TBL] [Abstract][Full Text] [Related]
56. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Larizza L; Magnani I; Beghini A
Leuk Lymphoma; 2005 Feb; 46(2):247-55. PubMed ID: 15621809
[TBL] [Abstract][Full Text] [Related]
57. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
58. Identification of AML1-ETO modulators by chemical genomics.
Corsello SM; Roti G; Ross KN; Chow KT; Galinsky I; DeAngelo DJ; Stone RM; Kung AL; Golub TR; Stegmaier K
Blood; 2009 Jun; 113(24):6193-205. PubMed ID: 19377049
[TBL] [Abstract][Full Text] [Related]
59. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
60. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
